Wishing you all the joys of the season! 
North America Glioma Treatment Market Forecast to 2030
North America Glioma Treatment Market Forecast to 2030 – Regional Analysis – by Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), and End User (Hospital & Clinics and Ambulatory Surgical Center)
$2,485 – $3,885
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Initiatives by Regional and State Governments to Provide Patients Access to Treatment Fuels North America Glioma Treatment Market
In December 2021, the Patient Access Network (PAN) Foundation and the American Brain Tumor Association announced a new partnership to support persons with glioblastoma by offering financial assistance for services worth up to US$ 1,600 per year for patients. Moreover, leading companies in the North America glioma treatment market focus on launching new products and developing existing ones. In December 2020, CNS Pharmaceuticals, Inc. announced the authorization of the use of berubicin by the Food and Medication Administration to treat patients with glioblastoma multiforme. In addition, the Food and Medication Administration designated LP-184 by Lantern Pharma Inc. as an orphan medication in August 2021 for treating glioblastoma multiforme and other malignant gliomas. A webinar on glioblastoma multiforme (GBM) and the potential of Lantern Pharma’s LP-184 for treating GBM and other types of brain cancer was also held in May 2020. Thus, efforts made by regional and state governments to provide patients with access to novel treatments accelerate the North America glioma treatment market growth.
North America Glioma Treatment Market Overview
The North America glioma treatment market in North America is segmented into the US, Canada, and Mexico; the US holds the largest share of the market in this region. The market growth is mainly attributed to the increasing brain tumor cases, rapid technological innovations, and developing healthcare infrastructure. According to a report published by the National Brain Tumor Society in 2023, glioblastoma is one of the deadliest, most complex, and treatment-resistant forms of cancer. Over 14,490 Americans are projected to receive a GBM diagnosis in 2023, accounting for ~50.1% of all primary malignant brain tumors. Prominent players in the North American market are focusing on various growth strategies such as mergers, acquisitions, partnerships, and new product launches to expand their geographic presence and enhance their product offerings. For instance, Elekta, a Sweden-based company, collaborated with GE Healthcare to bring innovations in the field of radiation oncology. Through this collaboration, hospitals would be provided with a wide range of treatments for cancer patients requiring radiation therapy.
The US holds a significant share of the North America glioma treatment market in North America. The market growth in this country is primarily driven by the increasing prevalence of brain tumor, growing technological advancements in glioma treatment, and the rising number of smokers. According to the American Society of Clinical Oncology (ASCO), in 2022, nearly 24,530 adults (13,840 men and 10,690 women) are estimated to be diagnosed with primary cancerous tumors of the brain and spinal cord in the US. Brain tumors are the primary central nervous system (CNS) malignancies, which account for 85-90% of all primary CNS cases. The demand for faster treatment is growing with the rising number of brain tumor cases. According to the Brain Tumor Registry of Canada, 4 out of 100,000 people in Canada suffer from glioblastoma, and nearly 1,000 Canadians are diagnosed with glioblastoma each year. The glioblastoma treatment market players are adopting various organic and inorganic strategies to succeed in the Canadian market. In February 2021, Medexus Pharmaceuticals Inc. initiated the commercial launch of Gleolan in Canada, which was previously only distributed under the Health Canada special access program. Gleolan is an imaging agent that causes high-grade gliomas (malignant and rapidly progressing brain tumors) to fluoresce under blue light, helping neurosurgeons better visualize these gliomas for complete removal. There are currently no other approved optical imaging agents in Canada for visualizing malignant tissues during glioma surgery. Further, developing healthcare infrastructure, increasing investments in research & development, and improvements in treatment procedures are anticipated to drive the North America glioma treatment market in Mexico during the forecast period.
North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Million)
North America Glioma Treatment Market Segmentation
The North America glioma treatment market is segmented into disease, treatment type, grade, end user, and country.
Based on disease, the North America glioma treatment market is segmented into astrocytoma, oligoastrocytoma, and oligodendroglioma. The astrocytoma segment held the largest share of the North America glioma treatment market in 2022.
Based on treatment type, the North America glioma treatment market is segmented into surgery, chemotherapy, radiation therapy, and others. The surgery segment held the largest share of the North America glioma treatment market in 2022.
Based on grade, the North America glioma treatment market is segmented into low grade and high grade. The high grade segment held a larger share of the North America glioma treatment market in 2022.
Based on end user, the North America glioma treatment market is segmented into hospital & clinics and ambulatory surgical center. The hospital & clinics segment held a larger share of the North America glioma treatment market in 2022.
Based on country, the North America glioma treatment market is segmented into Germany, the US, Canada, and Mexico. The US dominated the North America glioma treatment market in 2022.
Amgen Inc, Amneal Pharmaceuticals Inc, Arbor Pharmaceuticals LLC, Biocon Ltd, F. Hoffmann-La Roche Ltd, Karyopharm Therapeutics Inc, Merck & Co Inc, Pfizer Inc, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the North America glioma treatment market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to the research team’ research, the North America glioma treatment market was valued at US$ 2,179.88 million in 2022 and is expected to reach US$ 4,377.38 million by 2030, registering a CAGR of 9.1% from 2022 to 2030. Increase in prevalence of high-grade glioma and increasing drug approval for glioma treatment are among the critical factors attributed to the North America glioma treatment market expansion.
In recent years, there has been a notable increase in the approval of drugs to treat gliomas, marking a significant step forward in addressing the challenges posed by these severe brain tumors. Growing awareness of the urgent need for effective therapeutic options and the dedicated efforts of researchers and pharmaceutical companies to develop innovative treatments are leading to the development and approval of these drugs. Targeted therapies have been a key focus of researchers working on glioma treatment, wherein drugs are designed to specifically target molecular alterations or signaling pathways crucial for glioma cells’ survival and growth. These therapies aim to disrupt the tumor’s ability to expand while sparing healthy brain tissue. In June 2022, the FDA approved two targeted therapy drugs to be taken in combination—Dabrafenib and Trametinib. These drugs attack the cancerous cells that have undergone the BRAF mutation. The drugs stop the mutated cells from sending growth signals to other cells.
Drug manufacturers have been emphasizing the use of cutting-edge technologies. Kiyatec’s ex vivo 3D cell culture technology for high-grade glioma received new clinical data at ASCO 2022. Thus, an increasing number of drug approvals for treating glioma would result in notable growth trends in the North America glioma treatment market in the near future.
On the contrary, the high cost of diagnosis hampers the North America glioma treatment market.
Based on disease, the North America glioma treatment market is segmented into astrocytoma, oligoastrocytoma, and oligodendroglioma. The astrocytoma segment held 71.7% share of North America glioma treatment market in 2022, amassing US$ 1,563.97 million. It is projected to garner US$ 3,226.33 million by 2030 to expand at 9.5% CAGR during 2022-2030.
Based on treatment type, the North America glioma treatment market is segmented into surgery, chemotherapy, radiation therapy, and others. The surgery segment held 46.9% share of North America glioma treatment market in 2022, amassing US$ 1,023.24 million. It is projected to garner US$ 2,152.20 million by 2030 to expand at 9.7% CAGR during 2022-2030.
Based on grade, the North America glioma treatment market is segmented into low grade and high grade. The high grade segment held 79.5% share of North America glioma treatment market in 2022, amassing US$ 1,732.65 million. It is projected to garner US$ 3,594.10 million by 2030 to expand at 9.5% CAGR during 2022-2030.
Based on end user, the North America glioma treatment market is segmented into hospital & clinics and ambulatory surgical center. The hospital & clinics segment held 79.0% share of North America glioma treatment market in 2022, amassing US$ 1,721.50 million. It is projected to garner US$ 3,482.36 million by 2030 to expand at 9.2% CAGR during 2022-2030.
Based on country, the North America glioma treatment market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 83.9% share of North America glioma treatment market in 2022. It was assessed at US$ 1,828.84 million in 2022 and is likely to hit US$ 3,691.46 million by 2030, exhibiting a CAGR of 9.2% during 2022-2030.
Key players operating in the North America glioma treatment market are Amgen Inc, Amneal Pharmaceuticals Inc, Arbor Pharmaceuticals LLC, Biocon Ltd, F. Hoffmann-La Roche Ltd, Karyopharm Therapeutics Inc, Merck & Co Inc, Pfizer Inc, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd, among others.
o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America Glioma Treatment market.
o Highlights key in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the North America Glioma Treatment market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth North America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
TABLE OF CONTENTS
1. Introduction
1.1 The Research Team Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Glioma Treatment Market – Key Industry Dynamics
4.1 Market Drivers
4.1.1 Initiatives by Regional and State Governments to Provide Patients Access to Treatment
4.1.2 Increase in Prevalence of High-Grade Glioma
4.2 Key Market Restraints
4.2.1 High Cost of Diagnosis
4.3 Key Market Opportunities
4.3.1 Advancements in Healthcare Sector
4.4 Future Trends
4.4.1 Surge in Drug Approvals for Glioma Treatment
4.5 Impact Analysis:
5. Glioma Treatment Market – North America Market Analysis
5.1 North America Glioma Treatment Market Revenue (US$ Mn), 2022 – 2030
6. North America Glioma Treatment Market – Revenue and Forecast to 2030 – by Disease
6.1 Overview
6.2 North America Glioma Treatment Market Revenue Share, by Disease 2022 & 2030 (%)
6.3 Astrocytoma
6.3.1 Overview
6.3.2 Astrocytoma: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Oligoastrocytoma
6.4.1 Overview
6.4.2 Oligoastrocytoma: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
6.5 Oligodendroglioma
6.5.1 Overview
6.5.2 Oligodendroglioma: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
7. North America Glioma Treatment Market – Revenue and Forecast to 2030 – by Treatment Type
7.1 Overview
7.2 North America Glioma Treatment Market Revenue Share, by Treatment Type 2022 & 2030 (%)
7.3 Surgery
7.3.1 Overview
7.3.2 Surgery: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Chemotherapy
7.4.1 Overview
7.4.2 Chemotherapy: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Radiation Therapy
7.5.1 Overview
7.5.2 Radiation Therapy: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
8. North America Glioma Treatment Market – Revenue and Forecast to 2030 – by Grade
8.1 Overview
8.2 North America Glioma Treatment Market Revenue Share, by Grade 2022 & 2030 (%)
8.3 Low Grade
8.3.1 Overview
8.3.2 Low Grade: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
8.3.2.1 Grade I: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
8.3.2.2 Grade II: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
8.4 High Grade
8.4.1 Overview
8.4.2 High Grade: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
8.4.2.1 Grade III: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
8.4.2.2 Grade IV: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
9. North America Glioma Treatment Market – Revenue and Forecast to 2030 – by End User
9.1 Overview
9.2 North America Glioma Treatment Market Revenue Share, by End User 2022 & 2030 (%)
9.3 Hospital & Clinics
9.3.1 Overview
9.3.2 Hospital & Clinics: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Ambulatory Surgical Centers
9.4.1 Overview
9.4.2 Ambulatory Surgical Centers: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
10. North America Glioma Treatment Market – Country Analysis
10.1 Overview
10.1.1 North America Glioma Treatment Market, by Country
10.1.1.1 US
10.1.1.1.1 US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.1.2 US: North America Glioma Treatment Market, by Disease
10.1.1.1.3 US: North America Glioma Treatment Market, by Treatment Type
10.1.1.1.4 US: North America Glioma Treatment Market, by Grade
10.1.1.1.4.1 US: North America Glioma Treatment Market, by Low Grade
10.1.1.1.4.2 US: North America Glioma Treatment Market, by High Grade
10.1.1.1.5 US: North America Glioma Treatment Market, by End User
10.1.1.2 Canada
10.1.1.2.1 Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.2.2 Canada: North America Glioma Treatment Market, by Disease
10.1.1.2.3 Canada: North America Glioma Treatment Market, by Treatment Type
10.1.1.2.4 Canada: North America Glioma Treatment Market, by Grade
10.1.1.2.4.1 Canada: North America Glioma Treatment Market, by Low Grade
10.1.1.2.4.2 Canada: North America Glioma Treatment Market, by High Grade
10.1.1.2.5 Canada: North America Glioma Treatment Market, by End User
10.1.1.3 Mexico
10.1.1.3.1 Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.3.2 Mexico: North America Glioma Treatment Market, by Disease
10.1.1.3.3 Mexico: North America Glioma Treatment Market, by Treatment Type
10.1.1.3.4 Mexico: North America Glioma Treatment Market, by Grade
10.1.1.3.4.1 Mexico: North America Glioma Treatment Market, by Low Grade
10.1.1.3.4.2 Mexico: North America Glioma Treatment Market, by High Grade
10.1.1.3.5 Mexico: North America Glioma Treatment Market, by End User
11. North America Glioma Treatment Market Industry Landscape
11.1 Overview
11.2 Growth Strategies Done by the Companies in the Market, (%)
11.3 Organic Developments
11.3.1 Overview
11.4 Inorganic Developments
11.4.1 Overview
12. Company Profiles
12.1 F. Hoffmann-La Roche Ltd
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Arbor Pharmaceuticals LLC
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Merck & Co Inc
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Sun Pharmaceutical Industries Ltd
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Amgen Inc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Teva Pharmaceutical Industries Ltd
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Pfizer Inc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Amneal Pharmaceuticals Inc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Karyopharm Therapeutics Inc
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Biocon Ltd
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About Us
13.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Glioma Treatment Market Segmentation
Table 2. US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – Disease
Table 3. US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – Treatment Type
Table 4. US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 5. US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 6. US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 7. US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – End User
Table 8. Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – Disease
Table 9. Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – Treatment Type
Table 10. Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 11. Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 12. Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 13. Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – End User
Table 14. Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – Disease
Table 15. Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – Treatment Type
Table 16. Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 17. Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 18. Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 19. Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – End User
Table 20. Organic Developments Done By Companies
Table 21. Inorganic Developments Done By Companies
Table 22. Glossary of Terms, North America glioma treatment market
LIST OF FIGURES
Figure 1. North America Glioma Treatment Market Segmentation, By Country
Figure 2. North America Glioma Treatment Market – Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America Glioma Treatment Market Revenue (US$ Mn), 2022 – 2030
Figure 5. North America Glioma Treatment Market Revenue Share, by Disease 2022 & 2030 (%)
Figure 6. Astrocytoma: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Oligodendroglioma: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Oligodendroglioma: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. North America Glioma Treatment Market Revenue Share, by Treatment Type 2022 & 2030 (%)
Figure 10. Surgery: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Chemotherapy: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Radiation Therapy: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. North America Glioma Treatment Market Revenue Share, by Grade 2022 & 2030 (%)
Figure 15. Low Grade: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Grade I: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Grade II: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. High Grade: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Grade III: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Grade IV: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. North America Glioma Treatment Market Revenue Share, by End User 2022 & 2030 (%)
Figure 22. Hospital & Clinics: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 23. Ambulatory Surgical Centers: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. North America Glioma Treatment Market, 2022 ($Mn)
Figure 25. North America Glioma Treatment Market, By Key Countries, 2022 And 2030 (%)
Figure 26. US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 27. Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 28. Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 29. Growth Strategies Done by the Companies in the Market, (%)
The List of Companies – North America Glioma Treatment Market
1. Amgen Inc
2. Amneal Pharmaceuticals Inc
3. Arbor Pharmaceuticals LLC
4. Biocon Ltd
5. F. Hoffmann-La Roche Ltd
6. Karyopharm Therapeutics Inc
7. Merck & Co Inc
8. Pfizer Inc
9. Sun Pharmaceutical Industries Ltd
10. Teva Pharmaceutical Industries Ltd
You must be logged in to post a review.
Reviews
There are no reviews yet.